New Economic Analysis Based On Repatha ® (Evolocumab) Outcomes Data Published In JAMA Cardiology

Repatha Used in Patients at High-Risk For Cardiovascular Events is Cost-Effective at Net Prices at or Below $9,669 THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new Repatha® (evolocumab) economic analysis published in the Journal of the American Medical Association (JAMA) Cardiology. The study identifies the clinical and economic consequences of treating a population of patients at high-risk of cardiovascular (CV) events and defines the cost-effectiveness of Repatha under various clinical scenarios. The analysis is based on the clinical outcomes from the Repatha outcomes study (FOURIER) in patients with established atheroscleroti...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news